Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
55 hedge funds and large institutions have $21.2M invested in Asterias Biotherapeutics Inc. Series A in 2016 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 16 reducing their positions, and 4 closing their positions.
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
18% more capital invested
Capital invested by funds: $18M → $21.2M (+$3.17M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less funds holding
Funds holding: 56 → 55 (-1)
38% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 16
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $82K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$572K |
| 2 |
Citigroup
New York
|
+$21.4K |
| 3 |
State Street
Boston,
Massachusetts
|
+$19.3K |
| 4 |
ST
Spot Trading
Chicago,
Illinois
|
+$14.2K |
| 5 |
California State Teachers Retirement System (CalSTRS)
West Sacramento,
California
|
+$10.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIM
Spark Investment Management
New York
|
-$269K |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$208K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$75K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$32.7K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$25.8K |
AST Hedge Fund Activity: Q1 2016 in Review
55 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q1 2016, worth a combined $21.2M — up 18% from $18M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new AST positions and 4 closed out — a net gain of 1 holder — while 10 added to existing stakes and 16 trimmed.
The largest buyer was Thrivent Financial for Lutherans, adding an estimated $572K. The largest seller was Spark Investment Management, exiting entirely with an estimated $269K sold.
- 55 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q1 2016, down from 56 in Q4 2015.
- Funds reported $21.2M of Asterias Biotherapeutics Inc. Series A stock for Q1 2016, up 18% quarter-over-quarter.
- 5 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q1 2016 and 4 closed out, a net change of +1 holder.
- The largest Asterias Biotherapeutics Inc. Series A buyer in Q1 2016 was Thrivent Financial for Lutherans, an estimated $572K added.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q1 2016 was Spark Investment Management, an estimated $269K sold.
Based on aggregated 13F filings for Q1 2016.